Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyCarlo Visco, Ken H. Young, Emanuele S.G. dʼAmore et al.|Leukemia|2012Cited by 362
Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal CancerGregory J. Tsongalis, Kashyap Patel, William L Skinner et al.|American Journal of Clinical Pathology|2020Cited by 14
Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyCarlo Visco, Ken H. Young, Y Li et al.|Leukemia|2014Cited by 3
Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.Ken H. Young, Lin Wu, Nancy Patten et al.|Blood|2009Cited by 1